JGO Bhd. is a public listed pharmaceutical manufacturer of vaccines, started to develop a vaccine for...
Fantastic news! We've Found the answer you've been seeking!
Question:
Transcribed Image Text:
JGO Bhd. is a public listed pharmaceutical manufacturer of vaccines, started to develop a vaccine for Covid-19, named CCV-19 which has never been sold before in the market. Its accounting policy to the research and development of the vaccine is to capitalize on expenditure as far as allowed by the accounting standard. The expenditures incurred to 30 April 2020 of the vaccine were as follows: i. 1 May 2019 to 31 October 2019 JGO Bhd. commenced a research and development project of its new vaccine on 1 May 2019 to study the long term effect of the vaccine involving users' resistance to allergies and infections. On the same day, the vaccine production machine was purchased. On 31 October 2019, no worthwhile results with any particular applications have been obtained for the first phase. Details of expenditures incurred were as follows: Expenses Salaries paid to research team members Expenses on preparing technical feasibility Vaccine production machine with a useful life of 5 years Laboratory expenses Costs of materials used in the manufacturing process of the new vaccine ii. 1 November 2019 to 31 January 2020 JGO Bhd. has succeeded in developing the new vaccine on 1 November 2020 which will cure the Covid-19 more effectively than the other vaccine currently being marketed. The company was able to demonstrate that the production process met the criteria for recognition as an intangible asset on 31 January 2020. An enhancement process involving the vaccine was performed to enable additional uses of the vaccine and was targeted to boost sales. There is a definite demand for this vaccine and commercial production and sales would greatly exceed the costs of the new development. On 1 January 2020, JGO Bhd. applied for a patent on the vaccine and incurred legal and administrative costs. The development costs are to be amortized over a 10-year useful life. Details of expenditures incurred were as follows: Expenses Salaries paid to research team members RM 500,000 250,000 3,000,000 1,200,000 420,000 Design and construction of pre-prototype of the new vaccine Patents purchased with right of use for 5 years Market research to test for any evaluation of new vaccine Assessment of the commercial viability of the new vaccine Laboratory expenses RM 800,000 800,000 500,000 300,000 240,000 400,000 iii. 1 February 2020 to 30 April 2020 On 1 February 2020, JGO Bhd. launched the new vaccine, CCV-19 into the market. The feedback from the users was positive. On 1 April 2020, the company was also trying to develop a new vaccine, named CCV2 that will develop neutralizing antibodies to the virus at levels similar to people who had recovered from the infection. Although the company feels very confident about the development of this new vaccine, it has not yet succeeded in developing the right formula. Details of expenditures incurred were as follows: Expenses Product launching expenses for CCV-19 Quality control during commercial production of CCV-19 Salaries paid to research team members for the new vaccine, CCV2 Costs of materials used in the process of the new vaccine, CCV2 Laboratory expenses RM 1,200,000 200,000 1,000,000 200,000 600,000 Required: Discuss the accounting treatments of the internally generated intangible assets for each of the above phases under MFRS138 Intangible Assets. JGO Bhd. is a public listed pharmaceutical manufacturer of vaccines, started to develop a vaccine for Covid-19, named CCV-19 which has never been sold before in the market. Its accounting policy to the research and development of the vaccine is to capitalize on expenditure as far as allowed by the accounting standard. The expenditures incurred to 30 April 2020 of the vaccine were as follows: i. 1 May 2019 to 31 October 2019 JGO Bhd. commenced a research and development project of its new vaccine on 1 May 2019 to study the long term effect of the vaccine involving users' resistance to allergies and infections. On the same day, the vaccine production machine was purchased. On 31 October 2019, no worthwhile results with any particular applications have been obtained for the first phase. Details of expenditures incurred were as follows: Expenses Salaries paid to research team members Expenses on preparing technical feasibility Vaccine production machine with a useful life of 5 years Laboratory expenses Costs of materials used in the manufacturing process of the new vaccine ii. 1 November 2019 to 31 January 2020 JGO Bhd. has succeeded in developing the new vaccine on 1 November 2020 which will cure the Covid-19 more effectively than the other vaccine currently being marketed. The company was able to demonstrate that the production process met the criteria for recognition as an intangible asset on 31 January 2020. An enhancement process involving the vaccine was performed to enable additional uses of the vaccine and was targeted to boost sales. There is a definite demand for this vaccine and commercial production and sales would greatly exceed the costs of the new development. On 1 January 2020, JGO Bhd. applied for a patent on the vaccine and incurred legal and administrative costs. The development costs are to be amortized over a 10-year useful life. Details of expenditures incurred were as follows: Expenses Salaries paid to research team members RM 500,000 250,000 3,000,000 1,200,000 420,000 Design and construction of pre-prototype of the new vaccine Patents purchased with right of use for 5 years Market research to test for any evaluation of new vaccine Assessment of the commercial viability of the new vaccine Laboratory expenses RM 800,000 800,000 500,000 300,000 240,000 400,000 iii. 1 February 2020 to 30 April 2020 On 1 February 2020, JGO Bhd. launched the new vaccine, CCV-19 into the market. The feedback from the users was positive. On 1 April 2020, the company was also trying to develop a new vaccine, named CCV2 that will develop neutralizing antibodies to the virus at levels similar to people who had recovered from the infection. Although the company feels very confident about the development of this new vaccine, it has not yet succeeded in developing the right formula. Details of expenditures incurred were as follows: Expenses Product launching expenses for CCV-19 Quality control during commercial production of CCV-19 Salaries paid to research team members for the new vaccine, CCV2 Costs of materials used in the process of the new vaccine, CCV2 Laboratory expenses RM 1,200,000 200,000 1,000,000 200,000 600,000 Required: Discuss the accounting treatments of the internally generated intangible assets for each of the above phases under MFRS138 Intangible Assets.
Expert Answer:
Answer rating: 100% (QA)
i 1 May 2019 to 31 October 2019 The expenditures incurred up to 31 October 2019 are considered to be ... View the full answer
Related Book For
Posted Date:
Students also viewed these accounting questions
-
Materials used in the manufacturing process that do not become a significant part of the finished products are called a. indirect materials. b. operating expenses. c. administrative expenses. d....
-
Health and Wealth Bhd (HWB) is a public listed company with a chain of 50 general department stores in Malaysia. The company is known for the high quality of its products, mainly food. The majority...
-
IT Sayang Bhd is a public listed company dealing with household utensil and equipment. The followings are the Statement of Financial Position of Sayang Bhd. Bayang Bhd and Dayang Bhd as at 31...
-
A job order cost accounting system is fully integrated into the general ledger of a company. Identify the major general ledger accounts used in a job order cost system. Explain how manufacturing...
-
Dutch Truck Sales sells semitrailers. The current inventory includes the following five semitrailers (identical except for paint color) along with purchase dates and costs: On May 20, 2011, a...
-
Check this in general, without picking values for r1 and r2. The geometry behind the geometric mean is based on the following argument. If a random variable R takes on each of the values r1 and r2...
-
Complete the proof of Proposition 5.2 for the third case \(x_{1}
-
The accountant of Latifa Shoe Co. has compiled the following information from the companys records as a basis for an income statement for the year ended December 31, 2014. Rent revenue...
-
Can you explain how to solve these problems and the formulas you used to get the answer . Consider the following multifactor (APT) model of security returns for a particular stock. Factor Risk Fac...
-
Paolo is a 50% partner in the Capri Partnership and has decided to terminate his partnership interest. Paolo is considering two options as potential exit strategies. The first is to sell his...
-
WORKSHEET 2 Correlation: x, y 50 0.0 15 Method Correlation type Pearson Number of rows used 26 Correlations X y -0.874 CT E 02 C3 T=-0.874 CI=(-0.942, -0.736) C4 3.0 x C5 4.5 6.0 C6 Replicates 15%...
-
Write a main function/program that repeatedly generates and prints random integers in the range [1, 100]. The program must stop when the distance between successive printed values is less than 5. Two...
-
3. A 0.75-kg ball is attached to one end of a 1.25-m-long massless rod, and the other end of MEC200 the rod is hung from a pivot. Suppose the maximum height reached by the ball is such that the...
-
ROI, or return on investment is a common term used in business planning. We want to know whether or not an investment in a project is financially worthwhile or not. We use ROI to determine whether or...
-
You are a shareholder in a C corporation. The corporation earns $2.37 per share before taxes. Once it has paid taxes it will distribute the rest of its earnings to you as a dividend. Assume the...
-
Find all complex roots of the following equations: (a) z + 64 = 0 (b) z5 +243 = 0 Write the result in the conventional form, i.e., as a sum of the real and imaginary parts. Show all details of work.
-
Direct labor $8.75 per direct labor hour Machine processing $3.75 per machine hour Machine preparation $50 each preparation Production order $200 for each order Shipping and handling $150 per...
-
Give the products of the following reaction, where T is tritium: dioldehydrase Ad- CH CH3C-COH CoIII) coenzyme B12
-
It is Monday, September 16, 2013. You, CA, work at Fahmy & Gingras LLP, a CA ï¬rm. Ken Ndiaye, one of the partners, approaches you mid-morning regarding Brennan & Sons Limited (BSL), a...
-
An extract from the consolidated statement of Triangle Holdings Inc. and its subsidiary, Trico Ltd., as at December 31, 2013, is shown below. Triangle Holdings acquired all the share capital (cum...
-
Why is it important to identify transactions as current or previous period transactions?
-
Outline the steps in the fraud hypothesis testing approach. What are Type II errors? How does one avoid Type II errors?
-
You determine the following data about a local government in the southeast. Determine the ratios of unreserved fund balance and reserved fund balance to total revenues. Are these ratios favorable?...
-
Assume that Debt Service Expenditures is \(\$ 16.2\) million and Total Revenues is \(\$ 70.1\) million. Calculate the Debt Service/total revenue ratio. Is the ratio favorable?
Study smarter with the SolutionInn App